Clinical trial

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

NCT03706365

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Abemaciclib Normalized identity: abemaciclibView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Abiraterone acetate Normalized identity: abiraterone acetateView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Prednisone Normalized identity: prednisoneView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2, PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-11-26

PhasePHASE2 / PHASE3

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

AbemaciclibDRUG · verified · RxNorm: abemaciclib

PlaceboDRUG

Abiraterone acetateDRUG · verified · RxNorm: abiraterone acetate

PrednisoneDRUG · verified · RxNorm: prednisone

Sponsors & collaborators

Eli Lilly and Companylead sponsor

Mapped research locations

Los AngelesCalifornia, United States2 PhoenixArizona, United States2 ShanghaiShanghai Municipality, China2 HangzhouZhejiang, China2 ChangshaHunan, China2 MelbourneVictoria, Australia2 WuhanHubei, China2 TianjinTianjin Municipality, China2 BostonMassachusetts, United States1 AtlantaGeorgia, United States1 NashvilleTennessee, United States1 MadridSpain1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03706365 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.